SK Biopharmaceuticals Signs Supply Agreement with Subsidiary for Cenobamate... No Impact on Consolidated Financials

Contract: SK Biopharmaceuticals enters into a supply agreement with its subsidiary SK Life Science, Inc. for cenobamate (XCOPRI) in the US market
Size: Approximately KRW 41.6 billion (USD 27.6 million, 5.9% of 2025 consolidated revenue), internal transaction not reflected in consolidated revenue
Period: May 27-28, 2026 (short-term purchase order), payment within 120 days after delivery
Investment Risk: No direct impact on shareholder value as it is an internal transaction; no upfront payment
[AI Comprehensive Analysis]: This contract is a routine internal supply agreement with no impact on consolidated financials, thus neutral for stock price. Investors should focus on actual sales trends of the new drug.